European Journal of Cancer
Volume 46, Issue 13 , Pages 2389-2398 , September 2010

Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines

  • C. Falandry

      Affiliations

    • Medical Oncology Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, Université Lyon 1, Lyon, France
    • Corresponding Author InformationCorresponding author at: Medical Oncology Unit, Centre Hospitalier Lyon Sud, 165, Chemin du Grand Revoyet, 69495 Pierre Bénite cedex, France. Tel.: +33 478864318; fax: +33 478864319.
    • ,
  • M. Campone

      Affiliations

    • Institut Régional du Cancer Nantes Atlantique, CLCC René Gauducheau, Centre de Recherche en Cancérologie, INSERM 892, Nantes, Saint Herblain, France
    • ,
  • G. Cartron

      Affiliations

    • Hematology Department, CHU Montpellier, UMR-CNRS5235, Université Montpellier, Montpellier, France
    • ,
  • D. Guerin

      Affiliations

    • A+A Healthcare Marketing Research, Lyon, France
    • ,
  • G. Freyer

      Affiliations

    • Medical Oncology Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, Université Lyon 1, Lyon, France

Received 6 February 2010 ,Revised 26 April 2010 ,Accepted 29 April 2010.

References 

  1. Asano S. Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Pediatr Hematol Oncol. 1991;13(4):400–413
  2. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18(20):3558–3585
  3. Komrokji RS, Lyman GH. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther. 2004;4(12):1897–1910
  4. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167
  5. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;(4):CD003189.
  6. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400–411
  7. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205
  8. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433–2453
  9. Greil R, Jost LM. ESMO recommendations for the application of hematopoietic growth factors. Ann Oncol. 2005;16(Suppl 1):i80–i82
  10. Greil R, Psenak O. Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol 2007;18(Suppl 2):ii89–91.
  11. Greil R, Psenak O, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2008;19(Suppl 2):ii116–8.
  12. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–1184
  13. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005;23(31):7974–7984
  14. Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18(8):1764–1770
  15. Harlan LC, Greene AL, Clegg LX, et al. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol. 2005;23(36):9079–9088
  16. Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1996;14(9):2511–2520
  17. Gautie L, Canal P, Menguy A, et al. Analysis of hematopoietic growth factor prescriptions in 19 French Cancer Centers. Bull Cancer. 1998;85(12):1043–1048
  18. Maurice-Tison S, Schuller MP, Salamon R. Prescription d’un facteur de croissance hématopoïétique, le lénograstime, en pratique courante. Résultats et commentaires, à partir d’une enquête nationale réalisée d’avril 1995 à mars 1996. La Presse Médicale. 1998;27(24):1203–1212
  19. McNeil C. NCCN guidelines advocate wider use of colony-stimulating factor. J Natl Cancer Inst. 2005;97(10):710–711
  20. Thevenot T, Cadranel JF, Di Martino V, et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology. 2007;45(2):377–383
  21. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35
  22. Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–731
  23. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205
  24. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25(25):3871–3876
  25. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–1439
  26. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. Jama. 2005;293(9):1073–1081
  27. Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16(2):716–724
  28. Masutani M, Ochi Y, Kadota A, et al. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?. Oncol Rep. 2000;7(2):305–310
  29. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma. 1997;25(3–4):289–300
  30. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol. 1998;16(1):255–260
  31. Masutani M, Tsujino I, Fujie T, et al. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?. Oncol Rep. 1999;6(5):1045–1050
  32. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406–411
  33. Gatzemeier U, Kleisbauer JP, Drings P, et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol. 2000;23(4):393–400
  34. Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin’s lymphoma?. Brit J Cancer. 2004;90(7):1302–1305
  35. Hidalgo M, Mendiola C, Lopez-Vega JM, et al. A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998;83(4):719–725
  36. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651–2658
  37. Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 2005;23(28):6908–6918
  38. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl J Med. 1991;325(3):164–170
  39. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A(3):319–324
  40. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302–4311
  41. Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Brit J Haematol. 2003;122(3):413–423
  42. Burton C, Linch D, Hoskin P, et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin’s lymphoma. Brit J Cancer. 2006;94(6):806–813
  43. Tjan-Heijnen VC, Biesma B, Festen J, et al. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. J Clin Oncol. 1998;16(8):2708–2714

PII: S0959-8049(10)00372-2

doi: 10.1016/j.ejca.2010.04.031

European Journal of Cancer
Volume 46, Issue 13 , Pages 2389-2398 , September 2010

Article Tools

* Image Usage & Resolution